BPMUF
Basilea Pharmaceutica AGGrey Market
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Jun. 12, 2012, 8:19 AM

    (GSK) is making another bolt-on acquisition to strengthen its lineup, agreeing to pay an initial £146M ($227M) to acquire eczema drug Toctino from Swiss biotech Basilea (BPMUF.PK). GSK will pay another £50M if Toctino passes its Phase III trial and receives FDA approval, and royalties on U.S. sales starting three years after launch.

    | Jun. 12, 2012, 8:19 AM